Angiotensin‐converting enzyme inhibitors and bacterial pneumonia in patients with Parkinson disease. Issue 4 (16th January 2015)

• Record Type: Journal Article
• Authors: Wang, Han‐Cheng; Lin, Che‐Chen; Lau, Chi‐Ieong; Chang, Anna; Kao, Chia‐Hung
• Is Part Of: Movement disorders. Volume 30:Issue 4(2015)
• Page Start: 593
• Page End: 596
• Publication Date: 2015-01-16
• Subjects: Movement disorders -- Periodicals; 610
• DOI: 10.1002/mds.26136
• Languages: English
• ISSNs: 0885-3185

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="mds26136-sec-0001" sec-type="section"> <title>Background</title> <p>To evaluate the association of angiotensin‐converting enzyme inhibitors and angiotensin II receptor blockers with pneumonia development in patients with Parkinson's disease (PD).</p> </sec> <sec id="mds26136-sec-0002" sec-type="section"> <title>Methods</title> <p>The study cohort consisted of patients aged 50 years or older who were initially diagnosed with PD and had hypertension. We assessed the patients' exposure statuses and accumulated doses of angiotensin‐converting enzyme inhibitors and angiotensin II receptor blockers. We then evaluated the risk of pneumonia development in the patients who were exposed to these drugs and those who were not.</p> </sec> <sec id="mds26136-sec-0003" sec-type="section"> <title>Results</title> <p>We examined 2, 310 patients. During the observation period, 608 patients developed pneumonia. Angiotensin‐converting enzyme inhibitors were associated with a lower risk of pneumonia. This association was dose‐dependent.</p> </sec> <sec id="mds26136-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Angiotensin‐converting enzyme inhibitor use was associated with a dose‐dependent reduction in the risk of pneumonia in patients with PD and hypertension. © 2015 International Parkinson and Movement Disorder Society</p> </sec> </abstract>